Symbiotec Pharmalab IPO Closes With 75.08x Subscription
5paisa Capital Ltd
- 2 min read
Last Updated: 27th August 2026 - 07:23 pm
Symbiotec Pharmalab IPO was subscribed 75.08 times by 5:24 PM on Day 4, August 27, 2026. The public issue received bids for 93,54,86,175 shares against 1,24,60,533 shares available for subscription. The Qualified Institutional Buyers (QIBs) category recorded the highest subscription at 181.20 times, followed by Non-Institutional Investors (NIIs) at 77.56 times. The Employee (EMP) category subscribed 16.32 times, while Retail Investors subscribed 13.69 times.
Invest in Indian Markets and Unlock Future Potential With 5paisa!Subscription Status of Symbiotec Pharmalab IPO
| Date | QIB | NII | Retail | EMP | Total |
|---|---|---|---|---|---|
| Day 1 (August 24) | 0.37 | 1.03 | 0.96 | 1.59 | 0.81 |
| Day 2 (August 25) | 0.57 | 2.67 | 2.08 | 2.90 | 1.78 |
| Day 3 (August 26) | 0.62 | 11.99 | 5.18 | 6.03 | 5.34 |
| Day 4 (August 27) | 181.20 | 77.56 | 13.69 | 16.32 | 75.08 |
Here are the subscription details for Symbiotec Pharmalab IPO Day 4, as of 5:24 PM:
| Investor Category | Subscription (times) | Shares Offered | Shares bid for | Total |
|---|---|---|---|---|
| Anchor | 1 | 53,25,909 | 53,25,909 | 526.200 |
| QIB | 181.20 | 35,50,608 | 64,33,59,195 | 63,563.89 |
| NII | 77.56 | 26,62,955 | 20,65,35,120 | 20,405.67 |
| Retail | 13.69 | 62,13,562 | 8,50,46,805 | 8,402.62 |
| EMP | 16.32 | 33,408 | 5,45,055 | 53.85 |
| Total | 75.08 | 1,24,60,533 |
93,54,86,175 |
92,426.03 |
Key Highlights – Day 4
- Overall subscription stood at 75.08 times on Day 4 (August 27, 2026).
- Qualified Institutional Buyers (QIBs) subscribed 181.20 times, the highest.
- Non-Institutional Investors (NIIs) subscribed 77.56 times.
- Retail Investors subscribed 13.69 times.
- Employee (EMP) category subscribed 16.32 times.
Key Highlights – Day 3
- Overall subscription stood at 5.34 times on Day 3 (August 26, 2026).
- Qualified Institutional Buyers (QIBs) subscribed 0.62 times.
- Non-Institutional Investors (NIIs) subscribed 11.99 times, the highest.
- Retail Investors subscribed 5.18 times.
- Employee (EMP) category subscribed 6.03 times.
Key Highlights – Day 2
- Overall subscription stood at 1.78 times on Day 2 (August 25, 2026).
- Qualified Institutional Buyers (QIBs) subscribed 0.57 times.
- Non-Institutional Investors (NIIs) subscribed 2.67 times.
- Retail Investors subscribed 2.08 times.
- Employee (EMP) category subscribed 2.90 times, the highest.
Key Highlights – Day 1
- Overall subscription stood at 0.81 times on Day 1 (August 24, 2026).
- Qualified Institutional Buyers (QIBs) subscribed 0.37 times.
- Non-Institutional Investors (NIIs) subscribed 1.03 times.
- Retail Investors subscribed 0.96 times.
- Employee (EMP) category subscribed 1.59 times, the highest.
About Symbiotec Pharmalab Limited
Symbiotec Pharmalab Limited is a research-driven pharmaceutical and biotechnology company focused on active pharmaceutical ingredients (APIs) and complex pharmaceutical products. The company has capabilities across organic chemistry, biotechnology and complex injectables, with a significant presence in corticosteroid and steroidal-hormone APIs. Its portfolio also includes fermentation-based APIs and contract development and manufacturing services for pharmaceutical and nutraceutical companies. The company operates manufacturing facilities at Rau and Pithampur in Madhya Pradesh and supplies products to global markets.
- FREE IPO Application
- Apply with Ease
- Pre-Apply for IPOs
- UPI Bid Instantly
Trending on 5paisa
5paisa Capital Ltd
Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.